Collectively, these studies – encompassing cohorts ranging from 2,500 to 25,000 patients approximately – consistently show that BRAF V600E is associated with disease recurrence and adverse pathological features such as extrathyroidal extension and lymph node metastases. The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.